https://sel120inhibitor.com/pe....er-mentees-issues-in
It was a retrospective study of successive patients with EGFR-mutated (exon 19 or 21) NSCLC diagnosed between 01/2011 and 12/2014 during the Tianjin Medical University Cancer Institute Hospital and who had been finally diagnosed with BMs. The customers were stage I-III at preliminary presentation and developed BMs once the first progression. Overall survival (OS), OS after BM diagnosis (mOS), intracranial progression-free survival (iPFS), response to treatment, and side effects had bee
Like
Comment
Share
